English
简体中文
Total: £ 56.28
Published Date: 2024-11-25 | Pages: 131 | Tables: 206 | Pharma & Healthcare
Giant cell arteritis (GCA) is a granulomatous medium and large-vessel vasculitis. It is the most common form of systemic vasculitis, with an incidence of between 15 and 25 cases per 100,000 persons over 50 years of age.
The global market for Giant Cell Arteritis Therapeutic was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Giant Cell Arteritis Therapeutic was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Giant Cell Arteritis Therapeutic was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Giant Cell Arteritis Therapeutic was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Giant Cell Arteritis Therapeutic include Sanofi, Kiniksa Pharmaceuticals, Ltd., Regeneron, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Novartis AG, AbbVie, Inc., Bristol-Myers Squibb Company and Abbott, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Giant Cell Arteritis Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Giant Cell Arteritis Therapeutic by region & country, by Type, and by Application.
The Giant Cell Arteritis Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Giant Cell Arteritis Therapeutic.
Market Segmentation
By Company
Sanofi
Kiniksa Pharmaceuticals, Ltd.
Regeneron
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
Novartis AG
AbbVie, Inc.
Bristol-Myers Squibb Company
Abbott
Johnson & Johnson Services, Inc.
Johns Hopkins Hospital
Fortis Healthcare
American College of Rheumatology
Duke University Health System
Lahey Clinic Foundation
Segment by Type:
Prednisone
Methotrexate
Tocilizumab
Aspirin
Segment by Application
Corticosteroids
Immunosuppressive Agents
Anticoagulants
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Giant Cell Arteritis Therapeutic manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Giant Cell Arteritis Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Giant Cell Arteritis Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Giant Cell Arteritis Therapeutic Product Introduction
1.2 Global Giant Cell Arteritis Therapeutic Market Size Forecast
1.3 Giant Cell Arteritis Therapeutic Market Trends & Drivers
1.3.1 Giant Cell Arteritis Therapeutic Industry Trends
1.3.2 Giant Cell Arteritis Therapeutic Market Drivers & Opportunity
1.3.3 Giant Cell Arteritis Therapeutic Market Challenges
1.3.4 Giant Cell Arteritis Therapeutic Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Giant Cell Arteritis Therapeutic Players Revenue Ranking (2023)
2.2 Global Giant Cell Arteritis Therapeutic Revenue by Company (2019-2024)
2.3 Key Companies Giant Cell Arteritis Therapeutic Manufacturing Base Distribution and Headquarters
2.4 Key Companies Giant Cell Arteritis Therapeutic Product Offered
2.5 Key Companies Time to Begin Mass Production of Giant Cell Arteritis Therapeutic
2.6 Giant Cell Arteritis Therapeutic Market Competitive Analysis
2.6.1 Giant Cell Arteritis Therapeutic Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Giant Cell Arteritis Therapeutic Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Giant Cell Arteritis Therapeutic as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Prednisone
3.1.2 Methotrexate
3.1.3 Tocilizumab
3.1.4 Aspirin
3.2 Global Giant Cell Arteritis Therapeutic Sales Value by Type
3.2.1 Global Giant Cell Arteritis Therapeutic Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Giant Cell Arteritis Therapeutic Sales Value, by Type (2019-2030)
3.2.3 Global Giant Cell Arteritis Therapeutic Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Corticosteroids
4.1.2 Immunosuppressive Agents
4.1.3 Anticoagulants
4.1.4 Others
4.2 Global Giant Cell Arteritis Therapeutic Sales Value by Application
4.2.1 Global Giant Cell Arteritis Therapeutic Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Giant Cell Arteritis Therapeutic Sales Value, by Application (2019-2030)
4.2.3 Global Giant Cell Arteritis Therapeutic Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Giant Cell Arteritis Therapeutic Sales Value by Region
5.1.1 Global Giant Cell Arteritis Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Giant Cell Arteritis Therapeutic Sales Value by Region (2019-2024)
5.1.3 Global Giant Cell Arteritis Therapeutic Sales Value by Region (2025-2030)
5.1.4 Global Giant Cell Arteritis Therapeutic Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
5.2.2 North America Giant Cell Arteritis Therapeutic Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
5.3.2 Europe Giant Cell Arteritis Therapeutic Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
5.4.2 Asia Pacific Giant Cell Arteritis Therapeutic Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
5.5.2 South America Giant Cell Arteritis Therapeutic Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
5.6.2 Middle East & Africa Giant Cell Arteritis Therapeutic Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Giant Cell Arteritis Therapeutic Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Giant Cell Arteritis Therapeutic Sales Value
6.3 United States
6.3.1 United States Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
6.3.2 United States Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Giant Cell Arteritis Therapeutic Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
6.4.2 Europe Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Giant Cell Arteritis Therapeutic Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
6.5.2 China Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
6.5.3 China Giant Cell Arteritis Therapeutic Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
6.6.2 Japan Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Giant Cell Arteritis Therapeutic Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
6.7.2 South Korea Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Giant Cell Arteritis Therapeutic Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
6.8.2 Southeast Asia Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Giant Cell Arteritis Therapeutic Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Giant Cell Arteritis Therapeutic Sales Value, 2019-2030
6.9.2 India Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
6.9.3 India Giant Cell Arteritis Therapeutic Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Sanofi
7.1.1 Sanofi Profile
7.1.2 Sanofi Main Business
7.1.3 Sanofi Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.1.4 Sanofi Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.1.5 Sanofi Recent Developments
7.2 Kiniksa Pharmaceuticals, Ltd.
7.2.1 Kiniksa Pharmaceuticals, Ltd. Profile
7.2.2 Kiniksa Pharmaceuticals, Ltd. Main Business
7.2.3 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.2.4 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.2.5 Kiniksa Pharmaceuticals, Ltd. Recent Developments
7.3 Regeneron
7.3.1 Regeneron Profile
7.3.2 Regeneron Main Business
7.3.3 Regeneron Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.3.4 Regeneron Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.3.5 GlaxoSmithKline plc Recent Developments
7.4 GlaxoSmithKline plc
7.4.1 GlaxoSmithKline plc Profile
7.4.2 GlaxoSmithKline plc Main Business
7.4.3 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.4.4 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.4.5 GlaxoSmithKline plc Recent Developments
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 F. Hoffmann-La Roche Ltd. Profile
7.5.2 F. Hoffmann-La Roche Ltd. Main Business
7.5.3 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.5.4 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
7.6 Novartis AG
7.6.1 Novartis AG Profile
7.6.2 Novartis AG Main Business
7.6.3 Novartis AG Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.6.4 Novartis AG Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.6.5 Novartis AG Recent Developments
7.7 AbbVie, Inc.
7.7.1 AbbVie, Inc. Profile
7.7.2 AbbVie, Inc. Main Business
7.7.3 AbbVie, Inc. Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.7.4 AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.7.5 AbbVie, Inc. Recent Developments
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Profile
7.8.2 Bristol-Myers Squibb Company Main Business
7.8.3 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.8.4 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.8.5 Bristol-Myers Squibb Company Recent Developments
7.9 Abbott
7.9.1 Abbott Profile
7.9.2 Abbott Main Business
7.9.3 Abbott Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.9.4 Abbott Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.9.5 Abbott Recent Developments
7.10 Johnson & Johnson Services, Inc.
7.10.1 Johnson & Johnson Services, Inc. Profile
7.10.2 Johnson & Johnson Services, Inc. Main Business
7.10.3 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.10.4 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.10.5 Johnson & Johnson Services, Inc. Recent Developments
7.11 Johns Hopkins Hospital
7.11.1 Johns Hopkins Hospital Profile
7.11.2 Johns Hopkins Hospital Main Business
7.11.3 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.11.4 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.11.5 Johns Hopkins Hospital Recent Developments
7.12 Fortis Healthcare
7.12.1 Fortis Healthcare Profile
7.12.2 Fortis Healthcare Main Business
7.12.3 Fortis Healthcare Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.12.4 Fortis Healthcare Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.12.5 Fortis Healthcare Recent Developments
7.13 American College of Rheumatology
7.13.1 American College of Rheumatology Profile
7.13.2 American College of Rheumatology Main Business
7.13.3 American College of Rheumatology Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.13.4 American College of Rheumatology Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.13.5 American College of Rheumatology Recent Developments
7.14 Duke University Health System
7.14.1 Duke University Health System Profile
7.14.2 Duke University Health System Main Business
7.14.3 Duke University Health System Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.14.4 Duke University Health System Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.14.5 Duke University Health System Recent Developments
7.15 Lahey Clinic Foundation
7.15.1 Lahey Clinic Foundation Profile
7.15.2 Lahey Clinic Foundation Main Business
7.15.3 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Products, Services and Solutions
7.15.4 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue (US$ Million) & (2019-2024)
7.15.5 Lahey Clinic Foundation Recent Developments
8 Industry Chain Analysis
8.1 Giant Cell Arteritis Therapeutic Industrial Chain
8.2 Giant Cell Arteritis Therapeutic Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Giant Cell Arteritis Therapeutic Sales Model
8.5.2 Sales Channel
8.5.3 Giant Cell Arteritis Therapeutic Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Giant Cell Arteritis Therapeutic Market Trends
Table 2. Giant Cell Arteritis Therapeutic Market Drivers & Opportunity
Table 3. Giant Cell Arteritis Therapeutic Market Challenges
Table 4. Giant Cell Arteritis Therapeutic Market Restraints
Table 5. Global Giant Cell Arteritis Therapeutic Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Giant Cell Arteritis Therapeutic Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Giant Cell Arteritis Therapeutic Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Giant Cell Arteritis Therapeutic Product Type
Table 9. Key Companies Time to Begin Mass Production of Giant Cell Arteritis Therapeutic
Table 10. Global Giant Cell Arteritis Therapeutic Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Giant Cell Arteritis Therapeutic as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Giant Cell Arteritis Therapeutic Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Giant Cell Arteritis Therapeutic Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Giant Cell Arteritis Therapeutic Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Giant Cell Arteritis Therapeutic Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Giant Cell Arteritis Therapeutic Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Giant Cell Arteritis Therapeutic Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Giant Cell Arteritis Therapeutic Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Giant Cell Arteritis Therapeutic Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Giant Cell Arteritis Therapeutic Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Giant Cell Arteritis Therapeutic Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Giant Cell Arteritis Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Giant Cell Arteritis Therapeutic Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Giant Cell Arteritis Therapeutic Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Giant Cell Arteritis Therapeutic Sales Value by Region (2019-2024) & (%)
Table 27. Global Giant Cell Arteritis Therapeutic Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Giant Cell Arteritis Therapeutic Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Giant Cell Arteritis Therapeutic Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Giant Cell Arteritis Therapeutic Sales Value, (2025-2030) & (US$ Million)
Table 31. Sanofi Basic Information List
Table 32. Sanofi Description and Business Overview
Table 33. Sanofi Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 34. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of Sanofi (2019-2024)
Table 35. Sanofi Recent Developments
Table 36. Kiniksa Pharmaceuticals, Ltd. Basic Information List
Table 37. Kiniksa Pharmaceuticals, Ltd. Description and Business Overview
Table 38. Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 39. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of Kiniksa Pharmaceuticals, Ltd. (2019-2024)
Table 40. Kiniksa Pharmaceuticals, Ltd. Recent Developments
Table 41. Regeneron Basic Information List
Table 42. Regeneron Description and Business Overview
Table 43. Regeneron Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 44. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of Regeneron (2019-2024)
Table 45. Regeneron Recent Developments
Table 46. GlaxoSmithKline plc Basic Information List
Table 47. GlaxoSmithKline plc Description and Business Overview
Table 48. GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 49. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of GlaxoSmithKline plc (2019-2024)
Table 50. GlaxoSmithKline plc Recent Developments
Table 51. F. Hoffmann-La Roche Ltd. Basic Information List
Table 52. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 53. F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 54. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of F. Hoffmann-La Roche Ltd. (2019-2024)
Table 55. F. Hoffmann-La Roche Ltd. Recent Developments
Table 56. Novartis AG Basic Information List
Table 57. Novartis AG Description and Business Overview
Table 58. Novartis AG Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 59. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of Novartis AG (2019-2024)
Table 60. Novartis AG Recent Developments
Table 61. AbbVie, Inc. Basic Information List
Table 62. AbbVie, Inc. Description and Business Overview
Table 63. AbbVie, Inc. Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 64. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of AbbVie, Inc. (2019-2024)
Table 65. AbbVie, Inc. Recent Developments
Table 66. Bristol-Myers Squibb Company Basic Information List
Table 67. Bristol-Myers Squibb Company Description and Business Overview
Table 68. Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 69. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of Bristol-Myers Squibb Company (2019-2024)
Table 70. Bristol-Myers Squibb Company Recent Developments
Table 71. Abbott Basic Information List
Table 72. Abbott Description and Business Overview
Table 73. Abbott Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 74. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of Abbott (2019-2024)
Table 75. Abbott Recent Developments
Table 76. Johnson & Johnson Services, Inc. Basic Information List
Table 77. Johnson & Johnson Services, Inc. Description and Business Overview
Table 78. Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 79. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of Johnson & Johnson Services, Inc. (2019-2024)
Table 80. Johnson & Johnson Services, Inc. Recent Developments
Table 81. Johns Hopkins Hospital Basic Information List
Table 82. Johns Hopkins Hospital Description and Business Overview
Table 83. Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 84. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of Johns Hopkins Hospital (2019-2024)
Table 85. Johns Hopkins Hospital Recent Developments
Table 86. Fortis Healthcare Basic Information List
Table 87. Fortis Healthcare Description and Business Overview
Table 88. Fortis Healthcare Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 89. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of Fortis Healthcare (2019-2024)
Table 90. Fortis Healthcare Recent Developments
Table 91. American College of Rheumatology Basic Information List
Table 92. American College of Rheumatology Description and Business Overview
Table 93. American College of Rheumatology Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 94. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of American College of Rheumatology (2019-2024)
Table 95. American College of Rheumatology Recent Developments
Table 96. Duke University Health System Basic Information List
Table 97. Duke University Health System Description and Business Overview
Table 98. Duke University Health System Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 99. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of Duke University Health System (2019-2024)
Table 100. Duke University Health System Recent Developments
Table 101. Lahey Clinic Foundation Basic Information List
Table 102. Lahey Clinic Foundation Description and Business Overview
Table 103. Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Products, Services and Solutions
Table 104. Revenue (US$ Million) in Giant Cell Arteritis Therapeutic Business of Lahey Clinic Foundation (2019-2024)
Table 105. Lahey Clinic Foundation Recent Developments
Table 106. Key Raw Materials Lists
Table 107. Raw Materials Key Suppliers Lists
Table 108. Giant Cell Arteritis Therapeutic Downstream Customers
Table 109. Giant Cell Arteritis Therapeutic Distributors List
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
Table 113. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Giant Cell Arteritis Therapeutic Product Picture
Figure 2. Global Giant Cell Arteritis Therapeutic Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Giant Cell Arteritis Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 4. Giant Cell Arteritis Therapeutic Report Years Considered
Figure 5. Global Giant Cell Arteritis Therapeutic Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Giant Cell Arteritis Therapeutic Revenue in 2023
Figure 7. Giant Cell Arteritis Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Prednisone Picture
Figure 9. Methotrexate Picture
Figure 10. Tocilizumab Picture
Figure 11. Aspirin Picture
Figure 12. Global Giant Cell Arteritis Therapeutic Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 13. Global Giant Cell Arteritis Therapeutic Sales Value Market Share by Type, 2023 & 2030
Figure 14. Product Picture of Corticosteroids
Figure 15. Product Picture of Immunosuppressive Agents
Figure 16. Product Picture of Anticoagulants
Figure 17. Product Picture of Others
Figure 18. Global Giant Cell Arteritis Therapeutic Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Giant Cell Arteritis Therapeutic Sales Value Market Share by Application, 2023 & 2030
Figure 20. North America Giant Cell Arteritis Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Giant Cell Arteritis Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 22. Europe Giant Cell Arteritis Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Giant Cell Arteritis Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 24. Asia Pacific Giant Cell Arteritis Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia Pacific Giant Cell Arteritis Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 26. South America Giant Cell Arteritis Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 27. South America Giant Cell Arteritis Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Giant Cell Arteritis Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Giant Cell Arteritis Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 30. Key Countries/Regions Giant Cell Arteritis Therapeutic Sales Value (%), (2019-2030)
Figure 31. United States Giant Cell Arteritis Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 32. United States Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 33. United States Giant Cell Arteritis Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 34. Europe Giant Cell Arteritis Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 35. Europe Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 36. Europe Giant Cell Arteritis Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 37. China Giant Cell Arteritis Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 38. China Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 39. China Giant Cell Arteritis Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 40. Japan Giant Cell Arteritis Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 41. Japan Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 42. Japan Giant Cell Arteritis Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 43. South Korea Giant Cell Arteritis Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 44. South Korea Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 45. South Korea Giant Cell Arteritis Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 46. Southeast Asia Giant Cell Arteritis Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 48. Southeast Asia Giant Cell Arteritis Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 49. India Giant Cell Arteritis Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 50. India Giant Cell Arteritis Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 51. India Giant Cell Arteritis Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 52. Giant Cell Arteritis Therapeutic Industrial Chain
Figure 53. Giant Cell Arteritis Therapeutic Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
